Merck KgaA inks $11B Bio-Techne buyout to expand into cell therapy production

The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top